Enabling broad access to best-in-class CRISPR tools
Explore further
Explore further
MAD7® – a powerful, flexible, and cost-effective tool for precise genome modifications, designed to accelerate your R&D.
01
Affordable, Customized Licensing
MAD7 is available under a tailored license model, offering flexible terms to match your project’s scale and needs – without the restrictive fields and expensive fees often associated with other proprietary nucleases.
02
High Efficiency and Low Off-Target
Studies show MAD7 performs with strong on-target activity and reduced off-target effects, offering a reliable platform for genome-editing across a range of organisms.
03
Versatile and Precise
Using a unique TTTN PAM motif, MAD7 expands your genome-editing possibilities, allowing you to target sites previously unreachable by SpCas9. The result: greater flexibility in designing guides and making precise modifications.
04
Scalable Applications
From agricultural biotechnology and microbial engineering to human health and therapeutics, MAD7 lets you tackle a broad spectrum of genome-editing projects quickly and cost-effectively.
MAD7® lets you innovate with flexibility and confidence – unlocking possibilities in fields from drug development to food ingredient and small molecule production.
MAD7 is a licensing offering originally developed by Inscripta. In April 2025, Inscripta merged with Manus to create a leader in industrial biomanufacturing, establishing a unique end-to-end platform for development, scale-up, and commercialization of bioalternative products.
While Manus advances its integrated and proven scale-up platform, the MAD7 licensing program continues as an independent, standalone service.
Fully supported by Manus, it ensures MAD7 remains a trusted, widely available resource for researchers and partners worldwide.
Discover MAD7® – a flexible, cost-effective genome-editing tool designed to make R&D faster, simpler, and more accessible.
Download one-pager
Get in touch with Rob Evans from our Business Development team for technical or licensing support and to explore how to access best-in-class CRISPR tools.
